As part of the agreement, SOTIO will gain access to Synaffix’s ADC technologies, GlycoConnect, HydraSpace and toxSYN in an initial ADC program.
The company will also have the option to expand research and commercial licenses into two additional programs at a later date.
SOTIO will be responsible for the research, development, and commercialization of the ADCs, while Synaffix will manufacture the components specifically related to its proprietary technologies.
As a result, Synaffix will now be eligible to receive up to $740 million in payments spanning signature, target nomination and milestone payments plus additional royalties on commercial sales.
Peter van de Sande, head of Synaffix, said: “The selection of our ADC technologies by a seasoned ADC player like SOTIO is a strong recognition of the potential of these technologies to maximize the therapeutic index of ADCs. We look forward to partnering with SOTIO, and believe that with their singular focus on cancer immunotherapies and robust clinical pipeline, this partnership can deliver innovative medicines for patients in areas of high unmet medical need.”
Radek Spisek, CEO of SOTIO, added: “At SOTIO, we are building a broad pipeline of next-generation ADCs to address the challenges of solid tumors – and access to Synaffix’s ADC platform technologies will ensure we remain at the leading edge of this space. This collaboration combining SOTIO’s deep expertise in solid tumor drug development with Synaffix’s clinical-stage platform technology will drive important new innovations for the benefit of patients.”
Synaffix was fully acquired by Lonza in June 2023 and represents a newly formed ‘center of excellence’ for bioconjugation.